NET ASSET VALUE – 30 November 2025
On the 30 November 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,444 million and NAV per share was SEK 44.46.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 252 | 3.26 | 7.3% |
| Xspray Pharma | 18% | 245 | 3.17 | 7.1% |
| Empros Pharma | 79% | 204 | 2.64 | 5.9% |
| Atrogi | 44% | 197 | 2.54 | 5.7% |
| Lipum | 57% | 178 | 2.29 | 5.2% |
| KAHR Medical | 35% | 173 | 2.23 | 5.0% |
| Bonsai Biotherapeutics | 100% | 131 | 1.69 | 3.8% |
| Microbiotica | 10% | 125 | 1.62 | 3.6% |
| Xintela | 59% | 106 | 1.37 | 3.1% |
| Geneos Therapeutics | 12% | 91 | 1.18 | 2.6% |
| AnaCardio | 13% | 79 | 1.02 | 2.3% |
| Mendus | 23% | 72 | 0.93 | 2.1% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.70 | 1.6% |
| Vitara Biomedical | 11% | 47 | 0.61 | 1.4% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 0.9% |
| Egetis Therapeutics | 1% | 24 | 0.31 | 0.7% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2,033 | 26.25 | 59.0% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 5.9% |
| Symcel | 30% | 192 | 2.48 | 5.6% |
| Chromafora | 30% | 73 | 0.94 | 2.1% |
| Nanologica | 44% | 36 | 0.46 | 1.0% |
| Frontier Biosolutions | 2% | 26 | 0.34 | 0.8% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 529 | 6.82 | 15.3% | |
| Limited Partnerships, total | 109 | 1.40 | 3.2% | |
| Assets related to Portfolio companies | 316 | 4.08 | 9.2% | |
| Other assets and liabilities | 458 | 5.91 | 13.3% | |
| Net Asset Value | 3,444 | 44.46 | 100.0% | |